Dubey S - Search Results

1

EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.

Dubey S, Stephenson P, Levy DE, Miller JA, Keller SM, Schiller JH, Johnson DH, Kolesar JM; Eastern Cooperative Oncology Group. Dubey S, et al. J Thorac Oncol. 2006 Jun;1(5):406-12. J Thorac Oncol. 2006. PMID: 17409891 Free article. Clinical Trial.

2

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.

Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, Wilding G, Espinoza-Delgado I, Schiller JH. Traynor AM, et al. Among authors: dubey s. J Thorac Oncol. 2009 Apr;4(4):522-6. doi: 10.1097/jto.0b013e3181952478. J Thorac Oncol. 2009. PMID: 19347984 Free PMC article. Clinical Trial.

3

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM, Siegfried JM. Traynor AM, et al. Among authors: dubey s. Lung Cancer. 2009 Apr;64(1):51-9. doi: 10.1016/j.lungcan.2008.07.002. Epub 2008 Aug 12. Lung Cancer. 2009. PMID: 18701186 Free PMC article.

4

Chemotherapy for advanced non-small cell lung cancer.

Dubey S, Schiller JH. Dubey S, et al. Hematol Oncol Clin North Am. 2004 Feb;18(1):101-14. doi: 10.1016/s0889-8588(03)00135-7. Hematol Oncol Clin North Am. 2004. PMID: 15005284 Review.

5

Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer.

Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Dubey S, et al. J Support Oncol. 2005 Mar-Apr;3(2):149-54. J Support Oncol. 2005. PMID: 15796447

6

Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.

Dubey S, Schiller JH. Dubey S, et al. Oncologist. 2005 Apr;10(4):282-91. doi: 10.1634/theoncologist.10-4-282. Oncologist. 2005. PMID: 15821248 Free article. Review.

7

Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond.

Dubey S, Siegfried JM, Traynor AM. Dubey S, et al. Lancet Oncol. 2006 May;7(5):416-24. doi: 10.1016/S1470-2045(06)70693-3. Lancet Oncol. 2006. PMID: 16648046 Review.

8

Phase I study of docetaxel and topotecan in patients with advanced malignancies.

Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Dubey S, et al. J Oncol Pharm Pract. 2005 Dec;11(4):131-8. doi: 10.1191/1078155205jp161oa. J Oncol Pharm Pract. 2005. PMID: 16595064 Clinical Trial.

9

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. Dubey S, et al. J Thorac Oncol. 2010 Oct;5(10):1655-61. doi: 10.1097/JTO.0b013e3181ec18db. J Thorac Oncol. 2010. PMID: 20736856 Free PMC article. Clinical Trial.

10

Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.

Wakelee H, Dubey S, Gandara D. Wakelee H, et al. Among authors: dubey s. Oncologist. 2007 Mar;12(3):331-7. doi: 10.1634/theoncologist.12-3-331. Oncologist. 2007. PMID: 17405898 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,584 results

Search Page

Filters